{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:10:42Z","timestamp":1787008242840,"version":"build-2736575974"},"reference-count":39,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Dermatitis\u00ae"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Abstract:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Background:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    Some patients with atopic dermatitis (AD) do not sufficiently respond to upadacitinib, a Janus kinase 1 inhibitor. However, predictive factors for nonresponders remain unclear in real-world practice.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Objective:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    To identify predictive factors for primary and secondary nonresponders to upadacitinib 15 mg; primary nonresponders are defined as patients with investigator\u2019s global assessment (IGA) &gt;2 at week 12, while secondary nonresponders are defined as patients with IGA \u22642 at week 12 and IGA &gt;2 at week 24.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Methods:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    A prospective study was conducted from August 2021 to March 2024, involving 204 Japanese AD patients treated with upadacitinib 15 mg. Baseline clinical and laboratory indexes were compared between nonresponders and responders.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Results:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    Primary nonresponders showed higher baseline eczema area and severity index (EASI), immunoglobulin E (IgE), thymus and activation-regulated chemokine (TARC), lactate dehydrogenase (LDH), neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (CRP), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI) compared with responders. Secondary nonresponders had a higher proportion of previous systemic therapies, dupilumab, and corticosteroids.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Conclusions:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    Higher baseline EASI, IgE, TARC, LDH, NLR, CRP, SII, and SIRI may predict primary nonresponders to upadacitinib 15 mg, while previous systemic dupilumab or corticosteroids may predict secondary nonresponders.\n                  <\/jats:p>","DOI":"10.1089\/derm.2024.0445","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T03:16:31Z","timestamp":1733368591000},"page":"245-252","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Predictive Factors for Primary and Secondary Nonresponders to Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Study"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4183-9596","authenticated-orcid":false,"given":"Teppei","family":"Hagino","sequence":"first","affiliation":[{"name":"From the,  Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehisa","family":"Saeki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eita","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Fujimoto Dermatology Clinic, Funabashi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Kanda","sequence":"additional","affiliation":[{"name":"From the,  Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.12.646"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.02.008"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155664"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2023.100195"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2021.10.004"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19232"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.3023"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00588-2"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.11.025"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00589-4"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00798-0"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2022.4365"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.14139"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19581"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph17040519"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2344591"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-024-01352-4"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2276043"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2310643"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2291317"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2022.06.009"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16763"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2016.12.002"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1365544"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12440"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00120.2003"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14134"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.3109\/15569527.2013.834498"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2307489"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13061"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3838"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12062201"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2024.0445"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12083046"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1323174"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5701949"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23179553"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13230"},{"key":"e_1_3_1_40_2","article-title":"Effects of Tralokinumab on clinical and laboratory indexes in atopic dermatitis: A 24-Week Real-World Study","author":"Hagino T","year":"2024","unstructured":"Hagino T, , Onda M, , Saeki H, et al. Effects of Tralokinumab on clinical and laboratory indexes in atopic dermatitis: A 24-Week Real-World Study. Dermatitis. 2024.","journal-title":"Dermatitis"}],"container-title":["Dermatitis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/derm.2024.0445","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/derm.2024.0445","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/derm.2024.0445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T20:58:39Z","timestamp":1781557119000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/derm.2024.0445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3,1]]}},"alternative-id":["10.1089\/derm.2024.0445"],"URL":"https:\/\/doi.org\/10.1089\/derm.2024.0445","relation":{},"ISSN":["1710-3568","2162-5220"],"issn-type":[{"value":"1710-3568","type":"print"},{"value":"2162-5220","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]}}}